Blueprint Medicines Corp Stock Performance
| BPMC Stock | USD 93.08 2.19 2.30% |
Blueprint Medicines has a performance score of 1 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 1.29, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Blueprint Medicines will likely underperform. Blueprint Medicines Corp right now shows a risk of 3.65%. Please confirm Blueprint Medicines Corp expected short fall, day median price, and the relationship between the potential upside and accumulation distribution , to decide if Blueprint Medicines Corp will be following its price patterns.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Blueprint Medicines Corp are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of rather sound primary indicators, Blueprint Medicines is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
Actual Historical Performance (%)
One Day Return 7.38 | Five Day Return 7.33 | Year To Date Return 9.25 | Ten Year Return 404.88 | All Time Return 404.88 |
1 | Acquisition by Lee Philina of 4331 shares of Blueprint Medicines at 43.15 subject to Rule 16b-3 | 01/10/2025 |
2 | Blueprint Medicines Surges Over 10 percent as 2025 Growth Strategy Ignites Investor | 01/13/2025 |
3 | Disposition of 10000 shares by Albers Jeffrey W. of Blueprint Medicines at 36.05 subject to Rule 16b-3 | 01/21/2025 |
4 | Piper Sandler Sets New Price Target of 119.00 for Blueprint Medicines | 01/28/2025 |
5 | Blueprint Medicines projects 680M-710M AYVAKIT revenue in 2025 with 45 percent growth | 02/13/2025 |
6 | Disposition of 2274 shares by Christina Rossi of Blueprint Medicines at 95.14 subject to Rule 16b-3 | 02/20/2025 |
7 | Disposition of 400 shares by Haviland Kate of Blueprint Medicines at 95.4 subject to Rule 16b-3 | 02/21/2025 |
8 | Blueprint Medicines Corporation Among the Oversold Biotech Stocks to Buy Now | 02/24/2025 |
9 | Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI WAO Joint Congress | 02/28/2025 |
10 | Disposition of 1075 shares by Ariel Hurley of Blueprint Medicines at 95.16 subject to Rule 16b-3 | 03/03/2025 |
11 | Acquisition by Carter Percy H. of 11000 shares of Blueprint Medicines subject to Rule 16b-3 | 03/04/2025 |
12 | Disposition of 3530 shares by Carter Percy H. of Blueprint Medicines at 88.8 subject to Rule 16b-3 | 03/05/2025 |
13 | Disposition of 2541 shares by Hewes L. Becker of Blueprint Medicines at 87.98 subject to Rule 16b-3 | 03/06/2025 |
14 | Is Blueprint Medicines A Risky Investment | 03/07/2025 |
15 | Blueprint Medicines Co. Stock Holdings Lifted by Bank of New York Mellon Corp - Defense World | 03/10/2025 |
16 | Disposition of 1800 shares by Albers Jeffrey W. of Blueprint Medicines at 88.37 subject to Rule 16b-3 | 03/14/2025 |
17 | Is Blueprint Medicines Gaining Momentum in the Biotechnology Sector | 03/19/2025 |
| Begin Period Cash Flow | 81.5 M |
Blueprint |
Blueprint Medicines Relative Risk vs. Return Landscape
If you would invest 9,162 in Blueprint Medicines Corp on December 25, 2024 and sell it today you would earn a total of 146.00 from holding Blueprint Medicines Corp or generate 1.59% return on investment over 90 days. Blueprint Medicines Corp is currently generating 0.089% in daily expected returns and assumes 3.6515% risk (volatility on return distribution) over the 90 days horizon. In different words, 32% of stocks are less volatile than Blueprint, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Blueprint Medicines Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Blueprint Medicines' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Blueprint Medicines Corp, and traders can use it to determine the average amount a Blueprint Medicines' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0244
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | BPMC | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.65 actual daily | 32 68% of assets are more volatile |
Expected Return
| 0.09 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average Blueprint Medicines is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Blueprint Medicines by adding it to a well-diversified portfolio.
Blueprint Medicines Fundamentals Growth
Blueprint Stock prices reflect investors' perceptions of the future prospects and financial health of Blueprint Medicines, and Blueprint Medicines fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Blueprint Stock performance.
| Return On Equity | -0.31 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.13) % | ||||
| Operating Margin | (0.28) % | ||||
| Current Valuation | 5.94 B | ||||
| Shares Outstanding | 63.91 M | ||||
| Price To Earning | 7.93 X | ||||
| Price To Book | 20.39 X | ||||
| Price To Sales | 11.97 X | ||||
| Revenue | 508.82 M | ||||
| Gross Profit | 488.66 M | ||||
| EBITDA | (212.04 M) | ||||
| Net Income | (67.09 M) | ||||
| Cash And Equivalents | 853.11 M | ||||
| Cash Per Share | 14.28 X | ||||
| Total Debt | 126.05 M | ||||
| Debt To Equity | 0.14 % | ||||
| Current Ratio | 6.00 X | ||||
| Book Value Per Share | 4.69 X | ||||
| Cash Flow From Operations | (192.59 M) | ||||
| Earnings Per Share | (1.07) X | ||||
| Market Capitalization | 6.09 B | ||||
| Total Asset | 1.18 B | ||||
| Retained Earnings | (2.41 B) | ||||
| Working Capital | 481.88 M | ||||
| Current Asset | 170.42 M | ||||
| Current Liabilities | 18.64 M | ||||
About Blueprint Medicines Performance
By analyzing Blueprint Medicines' fundamental ratios, stakeholders can gain valuable insights into Blueprint Medicines' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Blueprint Medicines has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Blueprint Medicines has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 246.39 | 234.07 | |
| Return On Tangible Assets | (0.06) | (0.06) | |
| Return On Capital Employed | (0.23) | (0.24) | |
| Return On Assets | (0.06) | (0.06) | |
| Return On Equity | (0.22) | (0.21) |
Things to note about Blueprint Medicines Corp performance evaluation
Checking the ongoing alerts about Blueprint Medicines for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Blueprint Medicines Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Blueprint Medicines had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 508.82 M. Net Loss for the year was (67.09 M) with profit before overhead, payroll, taxes, and interest of 488.66 M. | |
| Blueprint Medicines Corp currently holds about 853.11 M in cash with (192.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.28. | |
| Blueprint Medicines has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from kalkinemedia.com: Is Blueprint Medicines Gaining Momentum in the Biotechnology Sector |
- Analyzing Blueprint Medicines' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Blueprint Medicines' stock is overvalued or undervalued compared to its peers.
- Examining Blueprint Medicines' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Blueprint Medicines' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Blueprint Medicines' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Blueprint Medicines' stock. These opinions can provide insight into Blueprint Medicines' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Blueprint Stock analysis
When running Blueprint Medicines' price analysis, check to measure Blueprint Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Blueprint Medicines is operating at the current time. Most of Blueprint Medicines' value examination focuses on studying past and present price action to predict the probability of Blueprint Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Blueprint Medicines' price. Additionally, you may evaluate how the addition of Blueprint Medicines to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |